Skip to main content

ODC Suspends Licences of Medicinal Cannabis Licence Holder

Published

The Office of Drug Control (ODC), within the Department of Health, has suspended Rapid Growth Pty Ltd’s (trading as Pure Cannabis Australia) medicinal cannabis and manufacture licences and associated permits, under the Narcotic Drugs Act 1967 (the Act), for a six-month period from 1 December 2021 to 31 May 2022, unless the Secretary of the Department of Health determines otherwise.

Rapid Growth Pty Ltd is prohibited from undertaking cannabis-related commercial activities, other than nurturing and tending to plants for the duration of the suspension.

Publication of this suspension assists other licence holders within the medicinal cannabis scheme, either with current or potential supply contracts with Rapid Growth Pty Ltd, to ensure they are adequately informed of Rapid Growth’s licence status.

If you suspect non-compliance in relation to medicinal cannabis cultivation or manufacture, you can report illegal or questionable practices to the ODC at ODC.Compliance@health.gov.au.

Audiences
  • Cultivators & producers
  • Manufacturers

Help us improve the Office of Drug Control site